Full-Time

Principal Project Engineer

Plastics

Posted on 9/12/2025

Insulet Corporation

Insulet Corporation

5,001-10,000 employees

Develops tubeless insulin pumps and pods

Compensation Overview

$139.7k - $209.6k/yr

+ No bonus + No equity + No benefits

Massachusetts, USA

Hybrid

Requires on-site work from an Insulet office at least 3-4 times a week.

Category
Mechanical Engineering (2)
,
Requirements
  • Bachelor’s degree in Engineering (Plastics, Mechanical, Manufacturing or Related)
  • Minimum 10+ years working experience in Plastics Injection Mold Tooling and/or Part Design
  • Working knowledge/experience in Scientific injection molding
  • Root Cause Analyses (RCA) skills
  • Understanding of components risk assessment/mitigation plans
  • Excellent communication skills
Responsibilities
  • Will serve as a plastics SME for the injection molding tooling and part design.
  • Fluent use of tooling design and DFM programs to design and standardize robust and optimum tools.
  • Run and analyze moldflow programs, create risk assessment reports and design proposals to mitigate risks.
  • Review and analyze plastic part design for optimum part design, create risk assessment, and recommend improvements.
  • Develop and standardize systems and policies about the management of tools, such as, and not limited to, the standardization of tools, processes for accepting tools through FAT, tool design specifications, lesson learned and improvement roll out from existing tools, new part/tool designs, etc
  • Understand, plan, and execute tool kick offs based on component demands and ramp.
  • Work with the commodity managers to develop a pipe line of cost savings initiatives
  • Participate actively in DFM projects to allow Insulet to scale efficiently at its current growth rate
  • Work with suppliers to understand all aspects of the manufacturing of plastics components
  • Proliferate the use of cavity pressure technology across the global supply base
  • Provide cost effective and technical solutions to new and existing molding cells
  • Specify and review designs for equipment, tooling, materials, and part designs
  • Apply advanced Engineering theories, principles, and methods to all things about molding.
  • Exercise decisions and judgment, utilizing advance Engineering techniques, about Engineering problems and proposals, applying expertise to solve simple and complex issues.
  • Lead the technical aspects, specifications, and designs of complete molding cells, including automation and vision inspection systems.
  • Be on the forefront of molding technology and propose new platforms for Insulet parts.
  • Responsible for ensuring that suppliers have accurate prints/BOM
  • All other duties as assigned
Desired Qualifications
  • Proficient at all aspects of injection molding processes/technologies- cube molds, two shot, stack.
  • Working knowledge of cavity pressure sensors
  • Full knowledge of all injection molding cells (machines, tools, hot runner systems, automation, vision systems, auxillary, etc)
  • Working knowledge of MS Office, including Office Project software
  • Six Sigma Process Improvement Experience/Certification
  • Outstanding team player who seeks and values diverse input to hone ideas, but who has the experience to develop strong starting proposals

Insulet Corporation designs, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its flagship product, the Omnipod, is a tubeless, waterproof insulin pump that delivers a continuous subcutaneous infusion of insulin through disposable pods controlled by a personal diabetes manager. The system works by wearing a pod on the body, programming insulin delivery via the PDM (or a connected device), and, in newer versions like Omnipod 5, integrating with continuous glucose monitors to automatically adjust insulin delivery. Compared with many competitors, Insulet emphasizes a tubeless, wireless pump with a disposable pod ecosystem, adding automated insulin delivery features and CGM integration to streamline diabetes care. The company aims to simplify and improve diabetes management, offering a convenient and discreet insulin delivery method to reduce the burden of daily diabetes care for users around the world.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $762M with 45% international growth and 25% customer base expansion.
  • Libre 3 Plus integration targets 450,000 users; Spain launches H2 2026.
  • Mike Panos appointed CCO March 30, 2026, drives global commercial strategy.

What critics are saying

  • Medtronic 780G captures 40% Europe share by 2025, erodes Omnipod dominance.
  • Abbott controls Libre 3 Plus supply, restricts interoperability within 6-18 months.
  • EVOLVE trial fails by 2027, derails type 2 closed-loop launch in 2028.

What makes Insulet Corporation unique

  • Omnipod 5 delivers tubeless, waterproof automated insulin delivery without needles.
  • FDA cleared Omnipod 5 for type 2 diabetes in August 2024, expanding market.
  • Pod platform adapts for non-insulin subcutaneous drugs in new therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 9th, 2026
Analysts see 75% upside on Insulet despite 11% drop in 2026

Insulet Corporation has a consensus analyst price target of $360, implying 75% upside, with over 90% of analysts maintaining bullish ratings as of 6 April 2026. However, shares have fallen over 11% year-to-date and hit a 52-week low of $202.44 on 2 April, down more than 16% from a year earlier. The medical device company, which manufactures the Omnipod tubeless insulin pump, appointed Mike Panos as executive vice president and chief commercial officer on 30 March to strengthen commercial capabilities. CEO Ashley McEvoy cited significant growth opportunities driven by expanding global adoption of automated insulin delivery systems as the standard of care for both type 1 and type 2 diabetes.

Massachusetts Life Sciences Center
Apr 2nd, 2026
MLSC partners highlight innovation and access at MassMEDIC Symposium and Gala.

MLSC partners highlight innovation and access at MassMEDIC Symposium and Gala. * April 2, 2026 As a proud sponsor of the 2026 MassMEDIC Medtech Impact Symposium and Gala, the Massachusetts Life Sciences Center (MLSC) joined partners and awardees from across the life sciences community to showcase the collaborations and investments driving meaningful progress for patients on a global scale. The Symposium brought together ecosystem leaders to explore how the medtech industry can deliver better outcomes while managing costs and sustaining innovation. In the afternoon, the Symposium shifted to three dynamic, concurrent panel tracks that examined the evolving landscape of healthcare delivery. Each panel featured practical, forward-looking dialogue focused on users, enabling technologies, and the accelerating shift in where care is delivered. MLSC-supported companies and partners played a key role throughout these discussions. Insulet Corporation, a crucial partner of the MLSC's Pathmaker program and a recipient of multiple Tax Incentive awards, participated in the panel, Everything, Everywhere, All the Time, which examined how healthcare systems balance quality, cost, and access in an increasingly complex environment. Panelists discussed how economic pressures, information gaps, and misaligned incentives continue to influence decision-making across the healthcare system. The MLSC has awarded Insulet with $16.3 million in tax incentives for the creation of 834 jobs. To date, the MLSC has invested $13.5 million in Pathmaker training organizations across Massachusetts, supporting more than 1,200 training opportunities and connecting graduates with 101 companies across the life sciences sector. Later in the afternoon, Gentuity, an industry partner of the MLSC's Bits to Bytes program, joined the panel, Talking Tech: Interventional Systems, where industry leaders shared perspectives on emerging trends and product innovation in interventional medical technologies. Through the Bits to Bytes program, the MLSC supports companies developing data-driven solutions that are advancing diagnosis and treatment. Over the past seven years, the program has awarded $27.6 million in capital funding to non-profit universities and academic medical centers who have partnered with companies like Gentuity, helping them bring cutting-edge technologies closer to patients. Rounding out the Symposium, MLSC COO Elizabeth Graham moderated a panel on assistive and autonomous technologies in clinical workflows, joined by leadership members of Johnson & Johnson MedTech - a longtime sponsor of the MLSC's Massachusetts Next Generation (MassNextGen) Initiative - and Robeauté, a company pioneering a new class of therapeutic microrobots. The discussion explored how tools such as surgical robotics, fully automated technologies, and critical care technologies are transforming care delivery, and examined the growing intersection of human expertise and automation. Since its founding in 2018, the MLSC's MassNextGen portfolio has grown to 39 companies, including 19 previous awardees that have raised seed or Series A financing. To date, MassNextGen companies have raised more than $401 million in follow-on funding. Reflecting the program's strong support for medical innovation, 28 percent of MassNextGen companies are developing novel technologies in the medical device space with the goal of improving patients' lives around the world. The day concluded with the Medtech Impact Gala, where the themes of the Symposium were reflected through powerful stories from patients and innovators. The evening celebrated the real-world impact of medical technology and recognized the individuals and organizations working to improve care around the world. The MLSC was proud to sponsor this event alongside several industry leaders and Tax Incentive awardees, including Insulet Corporation, Optikos, TransMedics, and ZOLL. Applications for several MLSC programs are now open, including Pathmaker, and both Impact Catalyst and MassNextGen with a deadline of June 12, 2026, at 1 p.m. EST. Announcements

Yahoo Finance
Apr 1st, 2026
Insulet appoints Mike Panos as CCO to drive global commercial strategy for diabetes tech platform

Insulet has appointed Mike Panos as Executive Vice President and Chief Commercial Officer to oversee its global commercial strategy and execution. The move follows strong quarterly results driven by the company's tubeless Pod insulin technology. Panos will lead global commercial strategy, market access and expansion into new geographies and patient segments. His appointment aligns with Insulet's focus on Omnipod 5 adoption and type 2 diabetes market penetration. The company's Q4 2025 revenue growth outpaced many patient monitoring peers, highlighting commercial momentum. Insulet's narrative projects $4.7 billion revenue and $716.9 million earnings by 2029, requiring 19.8% yearly revenue growth. However, investors face concentration risk around the Omnipod platform. Simply Wall St Community fair value estimates range widely, from $119.72 to $661,388.09, reflecting divergent views on the company's single-product strategy.

Yahoo Finance
Mar 31st, 2026
Insulet leads patient monitoring stocks with 31% revenue growth in Q4

Insulet reported Q4 revenues of $783.8 million, up 31.2% year on year, exceeding analysts' expectations by 2%. The diabetes care company, which develops tubeless insulin delivery systems through its Omnipod product line, delivered strong earnings with beats on both revenue and earnings per share estimates. The patient monitoring sector overall showed solid Q4 results, with the four tracked stocks beating revenue consensus estimates by 1.9% on average. However, next quarter's guidance came in 1.9% below expectations. Despite strong quarterly performance, Insulet shares have fallen 16% since reporting and currently trade at $206.93. The stock led the group in revenue growth but fell short of investor expectations, which may have been higher than published analyst projections.

Worcester Business Journal
Mar 30th, 2026
Insulet resurrects chief commercial officer role.

Insulet resurrects chief commercial officer role. March 30, 2026 Insulet has reinstated its chief commercial officer role after eliminating it three years ago. The Acton-based medical device manufacturer appointed Mike Panos to the resurrected position. Panos assumed his role as executive vice president, CCO of Insulet on Monday. In his new role, he will oversee the company's global commercial operations, including developing commercial strategies, growing market access, and supporting future growth, the company announced. Insulet develops and produces Omnipod, a line of tubeless insulin pumps for people with type 1 and type 2 diabetes. Panos' hiring comes as the company is implementing new strategies to strengthen its capabilities, said Insulet President and CEO Ashley McEvoy. Panos joins Insulet after working for three decades at Stryker, a Michigan-based medical device and equipment manufacturer. Panos began his tenure with the firm as a marketing associate in 1996, and most recently served as its leader, sales excellence, according to his LinkedIn profile. Panos graduated with his bachelor's and master's degrees from Boston College. Insulet originally eliminated its CCO position as part of an overall executive restructuring when Bret Christensen left the role to pursue another opportunity on May 5, 2023. Christensen's responsibilities were then split between Insulet's international general manager and U.S. general manager. As part of the reorganization, Insulet created a chief technology officer position and its first chief product and customer experience officer position. Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries. - Digital Partners -

INACTIVE